Predix says studies shows PRX-03140 improves cognitive performance, memory in Alzheimer's disease

By Lisa Kerner

Charlotte, N.C., July 18 - Predix Pharmaceuticals Holdings, Inc. said preclinical data from studies in Alzheimer's disease suggest that PRX-03140, a selective, proprietary serotonin 4 (5-HT4) receptor agonist, significantly improved cognitive performance and working memory.

Additionally, PRX-03140 increased levels of acetylcholine (ACh) in the brain and increased levels of brain nerve growth factor, which regulates nerve cell development, repair and regeneration.

The study data will be featured in an oral presentation at the 10th International Conference on Alzheimer's Disease in Madrid, Spain.

"We believe there is a significant unmet medical need for a well-tolerated, effective treatment for Alzheimer's disease that can be given once daily, and we are excited about the data we have seen in phase 1 trials of PRX-03140 in over 100 patients and healthy volunteers," president and chief executive officer Michael G. Kauffman said in a news release.

Alzheimer's disease, a debilitating neurodegenerative disorder characterized by progressive loss of memory and cognitive function, affects 4.5 million Americans.

Predix, based in Lexington, Mass., discovers and develops novel, highly selective, small-molecule drugs that target G-Protein Coupled Receptors and ion channels.

The company recently agreed to merge with EPIX Pharmaceuticals, Inc., based in Cambridge, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.